Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision tag updated to v3.3.4, replacing the previous v3.3.3; this is an internal versioning update with no effect on study content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T02:43:35.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    Footer updated to show Revision: v3.3.3; HHS Vulnerability Disclosure and Revision: v3.3.2 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-23T13:27:36.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Added a background citation: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer (N Engl J Med 2012;366:2455-2465) to the study page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-09T00:53:28.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The page shows a revision update from v3.3.1 to v3.3.2, a footer-level change that does not alter study details or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T18:51:33.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    Added Revision: v3.3.1 and removed the citation 'Safety and activity of anti-PD-L1 antibody in patients with advanced cancer' (N Engl J Med. 2012) along with Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T15:04:53.000Z thumbnail image
  8. Check
    64 days ago
    Change Detected
    Summary
    Added a reference: Pembrolizumab for the treatment of non-small-cell lung cancer (N Engl J Med. 2015;372:2018-2028). Removed a government funding status notice and a 1994 NEJM trial citation (preoperative chemotherapy plus surgery vs surgery alone).
    Difference
    0.6%
    Check dated 2025-11-17T07:44:08.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.